Edward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.
Edward A. Stadtmauer, MD, section chief, Hematologic Malignancies, and Roseman, Tart, Harrow, and Shaffer Families’ President’s Distinguished Professor, University of Pennsylvania, discusses the evolving treatment landscape in multiple myeloma.
Over the past 5 years, immunotherapy has garnered significant excitement in multiple myeloma, says Stadtmauer. Traditional immunotherapeutic agents for patients with multiple myeloma consisted of immunomodulatory agents, such as lenalidomide (Revlimid), pomalidomide (Pomalyst), and thalidomide (Thalomid). In addition, iberdomide, a next-generation cereblon E3 ligase modulator, is currently under investigation, Stadtmauer says.
Although these agents have expanded the armamentarium, the addition of monoclonal antibodies, such asdaratumumab (Darzalex) and elotuzumab (Empliciti), have transformed the up-front and relapsed/refractory treatment paradigms for patients with multiple myeloma, Stadtmauer concludes.